RxDoctor Payments Data

Michael Boyd, PA

Medical · Watkinsville, GANPI 1659315612

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $32,450 of the $41,716 with a category attached, or 77.8%. AbbVie accounts for 98.9% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2023 at $20,381 and has fallen 98.6% since, to $282 in 2025. Among medical clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$41,716in general payments, 2019–2025

Across 184 payments — averaging $226.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$41K
  • Amgen$120
  • Supernus Pharmaceuticals, Inc.$112
  • Otsuka America Pharmaceutical, Inc.$99
  • Sunovion Pharmaceuticals Inc.$40
  • AstraZeneca$35
  • plus $60 from 3 others

What the payments were for

  • Speaking & faculty fees$32,45078%
  • Travel & lodging$7,17917%
  • Food & beverage$2,0865%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$41,716 in reported general payments places this provider in the 95th percentile of 950 medical providers in Georgia.

See all medical providers in Georgia

Medicare billing

Part B allowed, 2024
$44,086
Medicare patients
267
Services billed
2,079

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl157$258,982
RexultiBrexpiprazole12$16,220
ZubsolvBuprenorphine Hcl/Naloxone Hcl12$11,195
Aripiprazole168$9,162
Trazodone Hcl371$6,557
Lurasidone Hcl35$5,372
Alprazolam614$4,752
Buprenorphine Hcl64$4,400
Venlafaxine Hcl ErVenlafaxine Hcl171$4,331
Doxepin Hcl147$3,994
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl42$3,837
Quetiapine Fumarate167$3,726
Atomoxetine Hcl38$3,484
Olanzapine125$3,246
Ziprasidone Hcl73$3,223

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$41,249$258,982157 claims
Otsuka America Pharmaceutical, Inc.Rexulti$99$16,22012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 950 medical providers in Georgia.

Other medical in Watkinsville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →